Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450160 | 0.88 | DHFR (0.56) | DHFRHTT | |
| SCHEMBL10488894 | 0.87 | DHFR (0.63) | DHFRHTT | |
| SCHEMBL1494254 | 0.85 | DHFR (0.56) | DHFRHTT | |
| SCHEMBL30215760 | 0.85 | DHFR (0.56) | DHFRHTT | |
| SCHEMBL10823014 | 0.83 | DHFR (0.60) | DHFRHTT | |
| SCHEMBL11555328 | 0.83 | P2RX3 (0.81) | DHFRHTT | |
| SCHEMBL27632116 | 0.83 | DHFR (0.60) | DHFRHTT | |
| Hydrochloric Acid SCHEMBL10822627 | 0.82 | DHFR (0.59) | DHFRHTT | |
| SCHEMBL11962147 | 0.81 | DHFR (0.65) | DHFRHTT | |
| SCHEMBL10488913 | 0.81 | CSF1R (0.68) | DHFRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20060142315-A1 | Substituted biaryl piperazinyl-pyridine analogues | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2006-06-29 | — | — | US | disclosed |
| WO-2004082613-A2 | 2,4-DIAMINO-5-[5’-SUBSTITUTED-BENZYL] PYRIMIDINES AND 2,4-DIAMINO-6-[5’-SUBSTITUTED-BENZYL] QUINAZOLINES | DANA FARBER CANCER INSTITUTE (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-0901473-A1 | NOVEL PIPERAZINYLALKYLTHIOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE NOVEL COMPOUNDS | EGIS GYOGYSZERGYAR RT. (HU) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997016429-A1 | NOVEL PIPERAZINYLALKYLTHIOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND A PROCESS FOR THE PREPARATION OF THE NOVEL COMPOUNDS | EGIS Gyógyszergyár Rt. (HU) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142315-A1 | Substituted biaryl piperazinyl-pyridine analogues | DHFR, DPYD, DLD | DHFR 1/4885HTT 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.